These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22948672)

  • 1. Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing.
    Lange MJ; Sharma TK; Whatley AS; Landon LA; Tempesta MA; Johnson MC; Burke DH
    Mol Ther; 2012 Dec; 20(12):2304-14. PubMed ID: 22948672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-protein interactions govern antiviral specificity and encapsidation of broad spectrum anti-HIV reverse transcriptase aptamers.
    Lange MJ; Nguyen PDM; Callaway MK; Johnson MC; Burke DH
    Nucleic Acids Res; 2017 Jun; 45(10):6087-6097. PubMed ID: 28334941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
    Joshi P; Prasad VR
    J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening inhibitory potential of anti-HIV RT RNA aptamers.
    Lange MJ; Burke DH
    Methods Mol Biol; 2014; 1103():11-29. PubMed ID: 24318883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes.
    Medina MF; Joshi S
    Nucleic Acids Res; 1999 Apr; 27(7):1698-708. PubMed ID: 10076002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
    Zhou C; Bahner I; Rossi JJ; Kohn DB
    Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus.
    Xing Z; Mahadeviah S; Whitton JL
    Antisense Res Dev; 1995; 5(3):203-12. PubMed ID: 8785476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.
    Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S
    Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines.
    Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells.
    Hormes R; Homann M; Oelze I; Marschall P; Tabler M; Eckstein F; Sczakiel G
    Nucleic Acids Res; 1997 Feb; 25(4):769-75. PubMed ID: 9016627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly.
    Westaway SK; Larson GP; Li S; Zaia JA; Rossi JJ
    Nucleic Acids Symp Ser; 1995; (33):194-9. PubMed ID: 8643367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes.
    Ramezani A; Ding SF; Joshi S
    Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
    Bai J; Banda N; Lee NS; Rossi J; Akkina R
    Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line.
    Michienzi A; Conti L; Varano B; Prislei S; Gessani S; Bozzoni I
    Hum Gene Ther; 1998 Mar; 9(5):621-8. PubMed ID: 9551610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.
    Yamada O; Kraus G; Luznik L; Yu M; Wong-Staal F
    J Virol; 1996 Mar; 70(3):1596-601. PubMed ID: 8627679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.